N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity By Ogkologos - January 23, 2026 131 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the I-PREDICT study Source RELATED ARTICLESMORE FROM AUTHOR Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma ESMO Calls for Cancer Care Integration in EU Global Health Resilience Initiative (GHRI) MOST POPULAR FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma August 22, 2025 Cancer in My Community: Advancements in Cancer Care in Singapore December 2, 2021 FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer January 29, 2026 Pursuing precision medicine in a flagship lung cancer trial July 15, 2020 Load more HOT NEWS ESMO Breast Cancer Congress 2023 Doing More—Together—to End Cancer as We Know It Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors...
